

# GP RESEARCH REVIEW™

Making Education Easy

Issue 181 – 2021

## In this issue:

- COVID-19 vaccine effectiveness
- Cognitive stimulation in the workplace, plasma proteins, and risk of dementia
- Pulmonary infection in elderly patients with heart failure
- α-adrenergic blockers for medical expulsion therapy of ureteral calculi
- Over-prescription of short-acting β-agonists for asthma
- ACEIs and ARBs and community-acquired pneumonia
- Influence of constipation on asthma
- Direct oral anticoagulants in morbidly obese patients with nonvalvular AF
- Probiotics in the treatment of functional abdominal pain in children
- Potential effects of pomegranate on rheumatoid arthritis

### Abbreviations used in this issue

**ACEI** = angiotensin-converting enzyme inhibitor  
**AF** = atrial fibrillation  
**aHR** = adjusted hazard ratio  
**ARB** = angiotensin II receptor blocker  
**BMI** = body mass index  
**CI** = confidence interval  
**COVID-19** = coronavirus disease 2019  
**CRP** = C-reactive protein  
**HR** = hazard ratio  
**IBD** = inflammatory bowel disease  
**LVEF** = left ventricular ejection fraction  
**NYHA** = New York Heart Association  
**OR** = odds ratio  
**RCT** = randomised controlled trial  
**RR** = risk ratio

**Welcome** to issue 181 of GP Research Review. A large population-based study from Ontario, Canada confirms that vaccination with two doses of mRNA COVID-19 vaccine is not only highly effective against symptomatic infection, but is also highly protective against severe outcomes in patients testing positive for SARS-CoV-2. A large international study has found that the risk of dementia in old age is lower in people with cognitively stimulating jobs than in those with non-stimulating jobs. In our Natural Health section, Dr Chris Tofield has reviewed two interesting studies, one investigating the use of probiotics in the treatment of functional abdominal pain in children, and the other, the potential effects of pomegranate on rheumatoid arthritis.

I hope you enjoy this issue and I welcome your comments and feedback.

Kind regards,

Jim

Assoc Professor Jim Reid

[jimreid@researchreview.co.nz](mailto:jimreid@researchreview.co.nz)

## Effectiveness of BNT162b2 and mRNA-1273 Covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe Covid-19 outcomes in Ontario, Canada

**Authors:** Chung H et al.

**Summary:** This study used data from Ontario to assess COVID-19 mRNA vaccine effectiveness against symptomatic infection and hospital admission or death among 324,033 people with symptoms of COVID-19. In total, 53,270 (16.4%) people were positive for SARS-CoV-2, of whom 2479 (4.7%) were admitted to hospital or died, and 21,272 (6.6%) had received at least one dose of vaccine. From 14 days after one dose, vaccine effectiveness against symptomatic infection was 60% (95% CI 57-64) and increased from 48% (95% CI 41-54) after 14-20 days to 71% (95% CI 63-78) after 35-41 days. Effectiveness ≥7 days after two doses was 91% (95% CI 89-93). Effectiveness against hospital admission or death ≥14 days after one dose was 70% (95% CI 60-77) and increased from 62% (95% CI 44-75) at 14-20 days to 91% (95% CI 73-97) at ≥35 days. Vaccine effectiveness ≥7 days after two doses was 98% (95% CI 88-100). Among adults aged ≥70 years, vaccine effectiveness was lower shortly after one dose but was similar to that in younger people after 28 days. Vaccine effectiveness was high against variants with the E484K mutation after two doses.

**Comment:** If only the vaccination doubters could read and have the ability to interpret the outcome of many studies like this that are appearing in the literature. There can now be no doubt of the effectiveness of COVID-19 vaccination, especially after two doses, including protection against the delta mutation. Will people never learn? Some of us remember polio, and for those younger, measles. Vitamin C and herbal remedies were a fat lot of use.

**Reference:** *BMJ*. 2021;374:n1943

[Abstract](#)

KINDLY SUPPORTED BY



Up to  
**1 IN 3 WOMEN**

who experienced a UTI  
in their life, will go on to suffer  
a recurrent UTI\*††

**NOW FULLY FUNDED<sup>2</sup>**

For protection against recurrent urinary tract  
infections\* prescribe **Hiprex™**

\*Recurrent UTIs: ≥2 in 6 months or ≥3 in 12 months\*

UTI: urinary tract infection  
UTI refers to cystitis


References: 1. Geerlings SE et al. Infect Dis Clin North Am 2014;28(1): 135-47. 2. PHARMAC <https://www.pharmac.govt.nz/news/notification-2019-11-08-flecainide-hexamine/>. Accessed 15/11/2019. Hiprex™ (hexamine Hippurate) is an antibacterial medicine for the prophylaxis and treatment of chronic and recurrent UTIs. **Dosage** is 1gm twice daily. May increase to 1 gm 3 times daily in patients with catheters. **Contraindications:** renal or severe hepatic insufficiency, severe dehydration and metabolic acidosis. **Precautions:** proteus or pseudomonas infection, pregnancy. **Adverse Effects:** GI upset, dysuria, rash. **Drug Interactions:** sulfonamides, alkalineisers. Take with food or ascorbic acid. (Nova Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Chatswood NSW 2067, Australia. Distributed in New Zealand by Radiant Health Ltd, c/- Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. Phone: 0508 375 394. TAPS PPS431. NZ-2020-03-0007. March 2020.

**hiprex**  
Urinary Tract Antibacterial

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW™ publication



**Jardiance®**  
(empagliflozin)

**FULLY FUNDED**  
with Special Authority criteria\*  
February 1st, 2021

**NEW. For your patients with type 2 diabetes<sup>†</sup>**

THE POWER TO ACCOMPLISH MORE  
Above and beyond glycaemic control<sup>†1,2</sup>

Click below to download your JARDIANCE resources

**PRESCRIBING GUIDE**    **PATIENT BOOKLET**


## Cognitive stimulation in the workplace, plasma proteins, and risk of dementia: Three analyses of population cohort studies


**Authors:** Kivimäki M et al.

**Summary:** This multinational analysis examined the relationship between cognitively stimulating work and dementia risk among 107,896 participants in 7 population-based prospective cohort studies from the IPD-Work (individual-participant data meta-analysis in working populations) consortium. Over 1.8-million-person years, 1143 people were diagnosed with dementia. Risk of dementia was lower among participants with high- versus low-cognitive stimulation at work (incidence 4.8 vs 7.3 per 10,000 person years; aHR 0.77; 95% CI 0.65-0.92) and the relationship was robust to adjustment for education, smoking, heavy alcohol consumption, physical inactivity, job strain, obesity, hypertension, diabetes, coronary heart disease and stroke (aHR 0.82; 95% CI 0.68-0.98). Higher cognitive stimulation at work was associated with lower levels of proteins that inhibit central nervous system axonogenesis and synaptogenesis (slit homologue 2 [SLIT2], carbohydrate sulfotransferase 12 [CHSTC], peptidyl-glycine  $\alpha$ -amidating monooxygenase [AMD]) and an increased dementia risk was associated with SLIT2 (aHR per standard deviation 1.16; 95% CI 1.05-1.28), CHSTC (aHR 1.13; 95% CI 1.00-1.27) and AMD (aHR 1.04; 95% CI 0.97-1.13).

**Comment:** Mmmmmmm. And I was thinking about retiring – one day. These studies suggest that riding off into the sunset increases the risk of dementia. Perhaps time to reflect and reconsider. If only golf and fishing were as stimulating as seeing patients – I still learn something every single day and long may I be privileged for it continue.

**Reference:** *BMJ.* 2021;374:n1804  
[Abstract](#)

 **Research Review**  
**New Zealand is now on LinkedIn.**  
[FOLLOW US TO KEEP UP TO DATE](#)



**Claim your CPD points for reading Research Reviews**

**FIND OUT MORE**

<sup>†</sup>38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).<sup>‡2</sup>  
\*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. <sup>†</sup>In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. <sup>‡</sup>The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).<sup>1,2</sup>


1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. *N Engl J Med.* 2015;373(22):2117-2128  
**JARDIANCE® empagliflozin 10mg, 25mg film coated tablets** Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>  
**INDICATION:** *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy* - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy* - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR  $\geq 30$  mL/min/1.73m<sup>2</sup> or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis); eGFR <30 mL/min/1.73m<sup>2</sup> or CrCl <30 mL/min. **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30 mL/min/1.73m<sup>2</sup>; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged  $\geq 75$  years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged  $\geq 75$  years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply; Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000370

 **Boehringer Ingelheim**  
Boehringer Ingelheim (NZ) Ltd.  
PO Box 76216 Manukau City,  
Auckland 2241. Phone 0800 802 461

  
Eli Lilly and Company (NZ) Ltd.  
PO Box 109197 Newmarket,  
Auckland 1149. Phone 0800 500 056  
NZBN 9429039560643



**PRADAXA®: The only NOAC with a  
SPECIFIC REVERSAL AGENT\***



**PRESCRIBING PRADAXA  
IS THINKING AHEAD<sup>1-3</sup>**  
The confidence of evidence with  
the reassurance of reversal<sup>2,4-7</sup>

NOAC: Non-Vitamin K Oral Anticoagulant. NVAf: Non Valvular Atrial Fibrillation. \*Praxbind consent to market 2015. References: 1. Pradaxa New Zealand approved data sheet March 2020. 2. Pollack CV, et al. N Engl J Med 2017;377:431-41. 3. Connolly SJ, et al. N Engl J Med 2009;361:1139-51. 4. Larsen TB, et al. BMJ 2016;353:113189 (and supplementary material). 5. Nielsen PB, et al. BMJ 2017;353:j510. 6. Roger KC, et al. Cardiol Rev 2016; 24(6):310-15. 7. Praxbind New Zealand approved data sheet Sept 2020.

PRADAXA® (dabigatran etexilate) 110 mg and 150 mg capsules ABRIDGED PRESCRIBING INFORMATION. Before prescribing, please review the full Data Sheet which is available on request from Boehringer Ingelheim or from <https://www.medsafe.govt.nz/Medicines/infoSearch.asp> INDICATION: Prevention of stroke, systemic embolism and reduction of vascular mortality in patients with nonvalvular atrial fibrillation with one or more of the following risk factors: previous stroke, transient ischaemic attack, or systemic embolism; left ventricular ejection fraction < 40%; symptomatic heart failure, ≥New York Heart Association Class 2; age ≥75 years; age ≥65 years associated with one of the following: diabetes mellitus, coronary artery disease or hypertension. DOSAGE: Usually 150 mg twice daily. Patients aged ≥80 years: 110mg twice daily. Patients aged 75 to 80 years or those with moderate renal impairment (CrCl 30-50 mL/min) with low thromboembolic risk and high bleeding risk: consider 110 mg twice daily. ADMINISTRATION: Take capsule whole with a glass of water, with or without food. Do not chew or open capsule. Assess renal function: prior to treatment initiation, in clinical situations that could lead to renal function decline, and at least once a year in patients with moderate renal impairment (CrCl 30-50 mL/min). CONTRAINDICATIONS: Known hypersensitivity to dabigatran or dabigatran etexilate or to one of the excipients. Severe renal impairment (CrCl <30 mL/min), Haemorrhagic manifestations, patients with a bleeding diathesis, or patients with spontaneous or pharmacological impairment of haemostasis. Organ lesions at risk of clinically significant bleeding, including haemorrhagic stroke within the last 6 months. Concomitant treatment with systemic ketoconazole. Prosthetic heart valve replacement. WARNINGS AND PRECAUTIONS: Haemorrhagic risk\*: moderate renal impairment (CrCl 30-50 mL/min), acetylsalicylic acid, NSAIDs, clopidogrel, congenital or acquired coagulation disorders, thrombocytopenia or functional platelet defects, active ulcerative gastrointestinal disease, recent gastrointestinal bleeding, recent biopsy or major trauma, recent intracranial haemorrhage, brain, spinal or ophthalmic surgery, bacterial endocarditis, age ≥75 years. Concomitant administration with: unfractionated heparins and heparin derivatives, low molecular weight heparins, fondaparinux, desirudin, thrombolytic agents, GPIIb/IIIa receptor antagonists, ticlopidine, dextran, sulfonpyrazone, rivaroxaban, prasugrel, ticagrelor, vitamin K antagonists, selective serotonin re-uptake inhibitors, selective serotonin norepinephrine reuptake inhibitors and the P-gp inhibitors (e.g. amiodarone, verapamil, quinidine, dronedarone, clarithromycin), itraconazole, tacrolimus, ciclosporin, ritonavir, tipranavir, nelfinavir and glecaprevir/pibrentasvir fixed-dose combination, P-gp inducers (e.g. rifampicin). Patients with antiphospholipid syndrome. Elevated liver enzymes >2 ULN. Surgical interventions may require temporary discontinuation of PRADAXA®. Pregnancy. Lactation. Children. Patients < 50 kg. \*For situation of life-threatening/uncontrolled bleeding, and in case of emergency surgery/urgent procedures when rapid reversal of the anticoagulation effects of PRADAXA is required, the specific reversal agent (PRAXBIND, idarucizumab) is available. ADVERSE EFFECTS: Common: Bleeding and signs of bleeding, anaemia, epistaxis, gastrointestinal haemorrhage, abdominal pain, diarrhoea, dyspepsia, nausea, skin haemorrhage, urogenital haemorrhage, haematuria. Serious: Major or severe bleeding, thrombocytopenia, neutropenia, agranulocytosis, drug hypersensitivity, angioedema, intracranial haemorrhage, haemoptysis. Others, see full Data Sheet. INTERACTIONS: See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS above. ACTIONS: Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma. Dabigatran prolongs the aPTT, ECT and TT. PRESCRIPTION MEDICINE PRADAXA® is fully funded with no special authority. PRADAXA® is a registered trademark of Boehringer Ingelheim. 27 November 2020

PRAXBIND® (idarucizumab, rch) 50 mg/mL solution for injection/infusion. ABRIDGED PRESCRIBING INFORMATION Before prescribing, please review the full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp> INDICATION: Specific reversal agent for dabigatran, indicated in patients treated with PRADAXA (dabigatran etexilate) when rapid reversal of the anticoagulant effects of dabigatran is required: for emergency surgery/urgent procedures, and in life-threatening or uncontrolled bleeding. DOSAGE: The recommended dose is 5 g. Two 50 mL vials (2 x 2.5 g) constitute one complete dose. ADMINISTRATION: The complete dose of 5 g is administered intravenously, as two consecutive infusions over 5 to 10 minutes each or as a bolus injection. For instructions for use / handling and restarting antithrombotic therapy, see full Data Sheet. CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS: Idarucizumab will not reverse the effects of other anticoagulants. Known hypersensitivity (weighed against potential benefit of emergency treatment) – discontinue PRAXBIND immediately in case of anaphylactic reaction or other serious allergic reaction. Hereditary fructose intolerance, controlled sodium diet. Pregnancy. Lactation. Children. Trade name and batch number should be recorded in patient file to improve traceability. See full Data Sheet. ADVERSE EFFECTS: No adverse events causally related to PRAXBIND have been identified. INTERACTIONS: Clinically relevant interactions with other medicinal products are not expected. ACTIONS: Idarucizumab is a humanised monoclonal antibody fragment (Fab) molecule derived from an IgG1 isotype antibody molecule, directed against the thrombin inhibitor dabigatran. PRESCRIPTION MEDICINE PRAXBIND® is a funded medicine – Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. PRAXBIND® is a registered trademark of Boehringer Ingelheim. 8 July 2019.

BOEHRINGER INGELHEIM (N.Z.) Ltd. 2 Osterley Way, Manukau City Auckland 2014.

PC-NI-100139, TAPS MR781



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

**Risk factors and management  
of pulmonary infection in elderly  
patients with heart failure:  
A retrospective analysis**

**Authors:** Peng Q & Yang Q

**Summary:** This single-centre, retrospective study (2018-20) evaluated pulmonary infection clinical characteristics and risk factors in 201 elderly heart failure patients. Incidence of pulmonary infection was 23.88% and there were differences ( $p < 0.05$ ) in age, diabetes status, NYHA grade, LVEF, and CRP between infection and non-infection groups. There were no differences in sex, BMI, alcohol intake, smoking, hypertension, hyperlipidaemia, and length of hospital stay between the groups. Logistic regression analyses suggested that age  $\geq 70$  years, diabetes, NYHA grade III, LVEF  $\leq 55\%$ , and CRP  $\geq 10$  mg/L were independent risk factors for pulmonary infection. The most common pathogens were *Pseudomonas aeruginosa* (34.48%), *Staphylococcus aureus* (19.57%), and *Klebsiella pneumoniae* (15.22%).

**Comment:** This study looked at 201 patients and showed that over a 2-year period, just over one-fifth of those in heart failure developed a pulmonary infection. There were large differences in the demographics of the group but the risk factors that particularly increased infection risk were age ( $>70$  years) NYHA failure grade III, LVEF  $<55\%$ , and CRP  $>10$ mg/L. Not so important were diabetes, alcohol consumption, hypertension, and hyperlipidaemia.

**Reference:** *Medicine (Baltimore)* 2021;100(38):e27238  
[Abstract](#)

**The efficacy and safety of  
alpha-adrenergic blockers for  
medical expulsion therapy in  
patients with ureteral calculi:  
A meta-analysis of placebo-  
controlled trials**

**Authors:** Yu Z-W et al.

**Summary:** This meta-analysis examined the use of  $\alpha$ -adrenergic blockers as a medical expulsive therapy (MET) in patients with ureteral calculi based on 8 placebo-controlled studies ( $n = 2284$ ). Overall,  $\alpha$ -adrenergic blockers had no effect on clearance of stones in the urinary tract (RR 1.05; 95% CI 1.00-1.11). Subgroup analysis suggested that  $\alpha$ -adrenergic blockers may be effective for distal urinary tract stones (RR 1.08; 95% CI 1.02-1.15). The combination of MET with  $\alpha$ -adrenergic blockers was associated with dizziness (RR 1.37; 95% CI 1.06-1.79) and retrograde ejaculation (RR 3.10; 95% CI 1.81-5.29).

**Comment:**  $\alpha$ -adrenergic blockers are recommended in New Zealand in Pathways to assist in treatment of ureteric stone clearance. This study was a meta-analysis of their use as compared to placebo. Eight studies were included with 2284 patients. And the outcome –  $\alpha$ -adrenergic blockers were no more effective than placebo, but subgroup analysis demonstrated that there was a marginal effect when the stone was distally placed. There was an expected large number of adverse effects in the blocker group, including dizziness (read postural hypotension).

**Reference:** *Medicine (Baltimore)* 2021;100(37):e27272  
[Abstract](#)





FOR WHEN YOUR PATIENT THOUGHT  
IT WAS A GOOD IDEA...

For effective relief of painful muscle spasms<sup>1</sup>

FULLY FUNDED<sup>2</sup>

**Norflex™**  
Orphenadrine Citrate 100mg

References: 1. NORFLEX Data Sheet. 2018. 2. PHARMAC Online Pharmaceutical Schedule - February 2020. NORFLEX is a prescription medicine. Please review the full Data Sheet before prescribing, available on the Medsafe website [www.medsafe.govt.nz](http://www.medsafe.govt.nz). NORFLEX Tablets are fully funded on the Pharmaceutical Schedule. NORFLEX™: Orphenadrine citrate 100 mg tablets. Indications: NORFLEX is indicated for the relief of stiffness and pain resulting from skeletal muscle spasm in sprains and strains, local muscle injury, prolapsed intervertebral disc, lumbago, fibrositis, non-articular rheumatism, acute toxicosis, surgery, fractures, anxiety and tension. Orphenadrine citrate has also been shown to be effective for treatment of tension headache and persistent hiccoughs. Contraindications: Hypersensitivity to orphenadrine, glaucoma, paralytic ileus, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the prostate or bladder neck, oesophageal spasm (megacystophagus) and myasthenia gravis. Warnings and Precautions: Hepatic, renal impairment, tachycardia, cardiac decompensation, coronary insufficiency or cardiac arrhythmias, glaucoma risk. Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, periodic monitoring of blood, urine and liver function values is recommended if orphenadrine is prescribed for prolonged use. Pregnancy and lactation: Safe use of orphenadrine has not been established with respect to adverse effects on foetal development. NORFLEX should therefore be used in women of childbearing potential and particularly during early pregnancy only when the potential benefits outweigh the risks. Orphenadrine is excreted in breast milk and is not recommended for use while breastfeeding. Effects on ability to drive and operate machinery: NORFLEX may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. Elderly patients: The elderly may be more susceptible to anticholinergic side effects and should be given a reduced dosage. Adverse Effects: common: dryness of mouth, tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Less common: transient episodes of light-headedness, dizziness or syncope. Infrequently, mental confusion in the elderly. These adverse reactions can usually be eliminated by reduction in dosage. Serious or life-threatening reactions: Very rare cases of aplastic anaemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established. Interactions: Confusion, anxiety and tremors have been reported in some patients receiving dextropropoxyphene or dextropropoxyphene combinations and orphenadrine concomitantly. Interactions have also been reported with phenothiazines and other drugs with anti-muscarinic properties. Avoid concomitant use of alcohol or other CNS depressants. Dosage and Administration: Adults - NORFLEX tablets: Two tablets per day, one in the morning and one in the evening. Children: not recommended for children under 12 years. (Nova Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Chatswood NSW 2067. Distributed in New Zealand by Radiant Health Ltd C/O Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. Free Phone 0508 375 394. NZ-2020-02-0003. TAPS NA 11684.



## Over-prescription of short-acting beta agonists in the treatment of asthma

Authors: Looijmans-van den Akker I et al.

**Summary:** This multicentre retrospective analysis of data from Dutch electronic medical records (n = 1161) examined the use of asthma medication in primary care and whether excessive short-acting  $\beta_2$ -agonist (SABA) use ( $\geq 400$  inhalations per year) was associated with poor asthma control and exacerbations. Among SABA recipients (n = 766), 193 (25%) overused SABAs, among whom 19% had an exacerbation versus 7% of appropriate SABA users. Among patients using asthma medication, the odds of having an exacerbation were 2.9-fold higher when using an inappropriate number of SABA inhalations (OR 2.897; 95% CI 1.87-4.48).

**Comment:** The fact that overuse of SABAs can lead to tachyphylaxis has been known since the early 80s. It has also been known since that time that the more they are used, the more unstable the asthma becomes. This study showed that 19% of inappropriate users suffered an exacerbation compared with 7% of those using them appropriately. Of all those using SABAs, 25% were using them inappropriately. The fact that they can provide instant gratification with relief of wheeze is a compelling reason for their use, but clinicians must get the message across that it is better to treat the cause of the symptoms rather than the symptoms themselves.

Reference: *Fam Pract.* 2021;38(5):612-616

[Abstract](#)

## Association between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and community-acquired pneumonia: A nationwide population propensity-score matching study

Authors: Lin S-Y et al.

**Summary:** This Taiwanese database analysis of community-acquired pneumonia examined its relationship with angiotensin-converting enzyme inhibitor (ACEI; n = 58,062) or angiotensin II receptor blocker (ARB; n = 67,944) use. The HR of community-acquired pneumonia for ARB users relative to non-ARB users was 0.33. The HR of community-acquired pneumonia was 0.71 in ACEI users versus nonusers. Stratification analysis suggested that ARB and ACEI both exhibited a protective effect for community-acquired pneumonia across age and sex. Recipients of ARBs for <100 days had a greater reduction in the risk of community-acquired pneumonia (adjusted HR [aHR] 0.58) than the non-ARB cohort, while ACEI recipients for 121-450 days were less likely to have community-acquired pneumonia (aHR 0.50).

**Comment:** ACEIs have long been associated with a side effect of cough, as have, to a much lesser extent, ARBs. This study looked at possible association with community-acquired pneumonia. In short, it showed that both had a protective effect on acquiring infection, with ARB users having an HR of 0.33 and ACEI patients having an HR of 0.71.

Reference: *Int J Clin Pract.* 2021;75(10):e14476

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

## Goodfellow Gems

### Long covid in patients who were not hospitalised

This is from an Arizona cohort of 303 non-hospitalised patients.<sup>1</sup> While some patients recover quickly, persistent symptoms are not uncommon. All patients had a positive covid test and were followed for a median of 61 days (range 30 to 250).

The paper reports on 28 symptoms. After 30 days, fatigue was reported in 37.5% of patients, and after 60 days, it was 47.1% (some lost to follow up). For breathlessness for those time periods, it was 37.5% and 45.5%. The 5th most common symptom was changes in smell or taste, 26.4% and 24.8. High blood pressure was present in 11.1% and 14.1%, respectively. The median number of symptoms was 3 (range 1 to 20).

The response rate to the initial questionnaire was 55.8% and was completed by 24/2/2021, so it is not clear if this included the delta variant.

References:

1. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. Plos One (2021) [View here](#)

Gems are chosen by the Goodfellow director Dr. Bruce Arroll to be either practice changing or practice maintaining. The information is educational and not clinical advice. [www.goodfellowunit.org/gems](http://www.goodfellowunit.org/gems)

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)



## The influence of constipation on asthma: A real-world, population-based cohort study

Authors: Huang Y-C et al.

**Summary:** This Taiwanese, nationwide, population-based cohort study of 86,860 constipated patients and 86,860 controls assessed the risk of asthma in constipated patients who might have altered gut microflora contributing to asthma via the gut-lung axis. Asthma incidence was higher in constipated than non-constipated patients (10.4 vs 5.7 per 1000 person-years) with a 1.81-fold greater risk after adjustment for age, gender, urbanisation, comorbidities, and medications (aHR 1.81; 95% CI 1.74-1.88). Subgroup analyses, suggested that patients aged 20-39 years had a 2.01-fold higher risk of asthma in the constipation cohort (95% CI 1.82-2.22). Severity of constipation was associated with increased risk of asthma, with an aHR of 1.92 (95% CI 1.84-2.00) for ≤30 days, 2.07 (95% CI 1.94-2.21) for 31-120 days, and 2.10 (1.96-2.25) for >120 days of laxative prescriptions (p < 0.001).

**Comment:** Fascinating. I know a little bit about asthma, and this is the first time that I have seen anything about its relationship with constipation. The asthma rate was doubled in the constipated group which had a 1.81-fold increase in risk as compared with the non-constipated. And the more severe the constipation, the greater the risk of asthma. I must say this is something I have not noticed clinically, but then again, I have never asked!!!!

Reference: *Int J Clin Pract.* 2021;75(10):e14540

[Abstract](#)

[CLICK HERE](#) to read previous issues of GP Research Review

## Direct oral anticoagulants versus warfarin in morbidly obese patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis

Authors: Mhanna M et al.

**Summary:** This systematic review and meta-analysis examined whether direct oral anticoagulants (DOACs) are effective and safe in morbidly obese patients (BMI >40 or weight >120 kg) with nonvalvular atrial fibrillation (NVAf) based on 10 studies including 89,494 patients on oral anti-coagulation therapy (DOACs n = 45,427; warfarin n = 44,067). The stroke or systemic embolism (SSE) rate was lower in DOAC than warfarin recipients (OR 0.71; 95% CI 0.62-0.81; p < 0.0001). The major bleeding rate was also lower with DOACs versus warfarin (OR 0.60; 95% CI 0.46-0.78; p < 0.0001). Subgroup analysis suggested that stroke or systemic embolism and major bleeding event rates were lower with rivaroxaban and apixaban than warfarin; however, dabigatran was noninferior to warfarin for stroke or systemic embolism rate but superior for major bleeding.

**Comment:** This meta-analysis of 10 studies including nearly 89,500 subjects looked at the efficacy and safety of DOACs compared to warfarin when used in the morbidly obese. Points of interest were embolic stroke, and major bleeding. DOACs (especially rivaroxaban and apixaban) were clearly superior to warfarin in outcome in both parameters, whereas dabigatran, while similar in embolic occurrence, was also superior in safety.

Reference: *Am J Ther.* 2021;28(5):e531-e539

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

### Independent commentary by Associate Professor Jim Reid



Jim Reid graduated in medicine at the University of Otago Medical School in Dunedin, New Zealand. He had previously trained as a pharmacist. He undertook postgraduate work at the University of Miami in Florida, USA. He headed the Department of General Practice and Rural Health at the Dunedin School of Medicine for over ten years and, following that, was Postgraduate Dean, acting Dean, and then Deputy Dean of the School for several years. Jim also has a private family medicine practice at the Meridian Medical Centre, Dunedin, New Zealand. He is a Life Member and a Distinguished Fellow of the Royal New Zealand College of General Practitioners and a Fellow of the American College of Chest Physicians. He serves on the scientific advisory panel of the NZ Asthma and Respiratory Foundation and is one of the authors of all three of the recently published guidelines - Children's Asthma, Adult and Adolescent Asthma, and COPD. He is also a director for the New Zealand Formulary. For full bio [CLICK HERE](#).

References: 1. Woodcock A et al. *Lancet* 2017;390:2247-2255. 2. GlaxoSmithKline New Zealand. Breo Ellipta Data Sheet. GSK NZ; 2018. Available at <https://medsafe.govt.nz/profs/datasheet/b/breoelliptainhalation.pdf>.

**Breo Ellipta** (fluticasone furoate/vilanterol trihydrate inhaler 100/25mcg per inhalation) is a **Prescription Medicine**. Breo Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta<sub>2</sub> agonist and inhaled corticosteroid) is appropriate. Breo Ellipta is also indicated for symptomatic treatment of adult patients with COPD with a FEV<sub>1</sub> <70% predicted normal (post-bronchodilator) and with an exacerbation history. **Breo Ellipta 100/25mcg is a fully funded medicine. Breo Ellipta 200/25mcg is a private purchase medicine (dose indicated in asthma only); a prescription charge will apply. Maximum Daily Dose:** In asthma adults and adolescents aged 12 years and over: One inhalation once daily. In COPD adults aged 18 years and over: One inhalation once daily. **Contraindications:** Patients with severe milk-protein allergy or those who have hypersensitivity to fluticasone furoate, vilanterol or any excipients. **Side Effects:** Candidiasis of mouth and throat, headache, nasopharyngitis, oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, dysphonia, upper

respiratory tract infection, bronchitis, influenza, abdominal pain, arthralgia, back pain, pyrexia, fractures. **Warnings and Precautions:** Not to be used for the treatment of acute asthma symptoms or an acute COPD exacerbation, for which a short-acting bronchodilator is required. Paradoxical bronchospasm may occur. Use care when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole), beta-blockers and in patients with severe cardiovascular disease, hepatic impairment, pulmonary tuberculosis, or in patients with chronic untreated infections. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. The incidence of pneumonia and fractures in patients with asthma was uncommon. Before prescribing Breo Ellipta, please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Breo and Ellipta are registered trade marks of the GlaxoSmithKline group of companies. Breo Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS DA2028AM-PM-NZ-FFV-ADVT-20JUN0006.**

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)





## ElimIn8 Educational Series on Hepatitis C

### Hepatitis C: A virus we can cure\* Treatment in Primary Care

Welcome to the full ElimIn8 Educational Series on Hepatitis C. The series consists of three short audio podcasts where health professionals discuss the role of primary care in the elimination of Hepatitis C from New Zealand.

You may have listened to some of these podcasts already but if not you can find them all in one place by clicking on the link below.

(\*Cure means no detectable HCV RNA is found in a blood test taken 12 weeks after treatment has finished.)

LISTEN TO THE SERIES



At all stages of your medical career, the NZMA is your voice, advocating on the issues that affect you, your colleagues and the health of all New Zealanders. A strong membership means we can do more.

Join us today.  
[www.nzma.org.nz](http://www.nzma.org.nz)  
or scan the code above



## EVIDENCE-BASED NATURAL HEALTH

by Dr Chris Tofield

### Use of probiotics in the treatment of functional abdominal pain in children – systematic review and meta-analysis

**Authors:** Trivić I et al.

**Summary:** This systematic review and meta-analysis examined probiotic effects of *Lactobacillus rhamnosus* GG and *Lactobacillus reuteri* DSM 17938 on functional abdominal pain in children based on 9 RCTs (n = 702). Children taking *L. reuteri* had reduction in pain intensity (mean difference -1.24; 95% CI -2.35 to -0.13) and an increase in the number of days without pain (mean difference 26.42 days; 95% CI 22.67-30.17). There were no differences for all other outcomes between probiotics and placebo.

**Comment:** *L. reuteri* has previously been shown to protect against nephropathy in diabetic mice, indicating a possible benefit that is yet to be studied in humans. This review, however, dealt with treatment of abdominal pain in children, for which probiotics are commonly used by parents. Unfortunately, other than achieving some reduction in pain intensity, *L. reuteri* failed to produce a significant impact on this all-too-common symptom in children.

**Reference:** *Eur J Pediatr.* 2021;180(2):339-351

[Abstract](#)

### Potential effects of pomegranate (*Punica granatum*) on rheumatoid arthritis: A systematic review

**Authors:** Malek Mahdavi A et al.

**Summary:** This systematic review of available evidence examined the potential properties of pomegranate (*Punica granatum*) on rheumatoid arthritis based on 12 studies. Human, animal, and *in vitro* studies indicated a potential beneficial effect of pomegranate on clinical symptoms, inflammatory and oxidative factors in rheumatoid arthritis by reducing inflammation and oxidative stress.

**Comment:** Pomegranate has been used for medicinal purposes for thousands of years and is now known as one of the superfoods. The authors' statement here that pomegranate can 'manage rheumatoid arthritis complications' may be a bit bold, but there is certainly merit in using this fruit or its extracts for its known antioxidant properties.

**Reference:** *Int J Clin Pract.* 2021;75(8):e13999

[Abstract](#)

### Dr Christopher Tofield



Dr Tofield completed his medical training at St Bartholomew's and the Royal London Hospital in London. He has extensive experience in general practice, spent several years in clinical research, has published several medical papers, is clinical advisor to Bay of Plenty District Health Board and practices skin cancer medicine and surgery. Chris also has a background in medical writing and editing and while at medical school published a medical textbook on pharmacology. Chris is responsible for sourcing and short-listing national and international studies for GP Research Review. He also selects papers and provides commentary for the Natural Health section in GP Research Review.

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

50% OFF  
ALL-ACCESS  
VIRTUAL PASS

Join us live and access all recorded material from all 8 2021 events hosted by the Australian & New Zealand Mental Health Association for HALF PRICE

MENTAL HEALTH  
AWARENESS MONTH  
EXCLUSIVE OFFER

USE DISCOUNT  
CODE **REREV15**



## Get your own copy of GP RESEARCH REVIEW

Become one of Research Review's  
32,000 health care subscribers

**SIMPLY CLICK**

**I am a Health Professional**

to send us an e-mail and we'll do the rest

